Dapagliflozin First Approved: FDA Timeline Since 2014
Dapagliflozin (Farxiga) first won FDA approval on January 8, 2014 for type 2 diabetes, then expanded to heart failure in 2020 and chronic kidney disease in 2021.
Dapagliflozin
6 source-based articles maintained by the HealthRX.com Editorial Team.
6articles
3topic areas covered
Jun 1, 2024latest review
Dapagliflozin library
Showing 6 of 6 clinical reviews.
Dapagliflozin Renal Dose: eGFR Thresholds Explained
Dapagliflozin stays at 10 mg daily regardless of kidney function. Starts at eGFR ≥25; continue until dialysis or transplant. DAPA-CKD data included.
Farxiga (Dapagliflozin) Safety in Older Adults 65 and Over
Evidence-based guide to dapagliflozin (Farxiga) safety in geriatric patients 65+, covering renal considerations, hypotension risk, fracture data, drug interactions, and deprescribing strategies.
Farxiga Hair and Skin Changes: What Dapagliflozin Does to Your Body
A guide to dapagliflozin (Farxiga) hair loss and skin changes, including genital mycotic infections, rash incidence from clinical trials, and what to do if symptoms appear.
Farxiga Sexual Function Impact: What Dapagliflozin Does (and Doesn't Do) to Libido, Erectile Function, and Genital Health
A guide to how dapagliflozin (Farxiga) affects sexual function in men and women with type 2 diabetes, heart failure, and CKD, including trial data, mechanistic explanations, and clinical management of genital mycotic infections.
How to Safely Stop Farxiga (Dapagliflozin): A Clinical Discontinuation Protocol
Dapagliflozin (Farxiga) has no FDA-labeled taper, but stopping removes diabetes, heart failure or kidney protection. Withhold it for 3 days before surgery.
